Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Silexion Therapeutics ( (SLXN) ) has provided an announcement.
On March 23, 2026, Silexion Therapeutics reconvened an extraordinary general meeting originally held on March 16, 2026, after the first session was adjourned for lack of quorum. Under its articles of association, the shareholders present after a 30‑minute lapse formed a valid quorum with approximately 36.6% of outstanding ordinary shares represented.
Shareholders voted on a proposal to increase authorized share capital by 50,000,000 ordinary shares, which received 38.2% of votes cast in favor and 61.8% against, and thus failed to obtain the required simple majority. A second proposal to amend the 2024 Equity Incentive Plan’s evergreen share pool to target 10% of fully diluted share capital also failed, receiving 40.7% support and 59.3% opposition, limiting the company’s immediate flexibility to expand its capital base and equity incentives.
The most recent analyst rating on (SLXN) stock is a Hold with a $1.00 price target. To see the full list of analyst forecasts on Silexion Therapeutics stock, see the SLXN Stock Forecast page.
Spark’s Take on SLXN Stock
According to Spark, TipRanks’ AI Analyst, SLXN is a Neutral.
The score is held down primarily by weak financial quality (no revenue and continued cash burn) and bearish technical positioning (below key moving averages with negative MACD). Positive corporate updates around the SIL204 program and regulatory/trial planning provide some offset, but valuation support is limited due to a negative P/E and no dividend.
To see Spark’s full report on SLXN stock, click here.
More about Silexion Therapeutics
Silexion Therapeutics Corp operates in the therapeutics and broader life sciences sector, focusing on the development of medical treatments supported by equity-based corporate financing structures. The company relies on its authorized share capital and equity incentive plans as key tools to fund operations, attract talent, and align employee and shareholder interests within the competitive biotech and pharma market.
Average Trading Volume: 40,480
Technical Sentiment Signal: Strong Sell
Current Market Cap: $4.06M
For an in-depth examination of SLXN stock, go to TipRanks’ Overview page.